Results: Surveys were returned by five Irish centres, representing a 42% response rate and one European centre. Significant variation was found in the mean DLP, CTDIvol and scan lengths. Based on the rounded 75th percentile of the mean DLP and CTDIvol, the proposed Irish DRL is 1025.41mGy cm and 20.97mGy, respectively. Based on the European survey the DRLs for DLP and CTDIvol were 680.12mGy cm and 21.85mGy, respectively. Material and Methods: Materials and methods : In this study were enrolled 48 patients with oral cancer diagnoses underwent postoperative RT or exclusive RT-CT treatment. The RT was performed with intensity-modulated radiotherapy (IMRT) technique and LINAC DHX of Varian System. All patients were treated at the department of Radiotherapy, University of Pisa. In patients non treated surgically or operated with major risk factors (positive margins, Extracapsular extension) RT treatment was performed in combination with chemotherapy (CT) or molecular-target therapy. Again patients operated with presence of minor risk factors (positive lymph nodes, lymphatic vascular invasion, perineural invasion) underwent only RT treatment. The volumes were defined as follows: PTV high risk: 66Gy (2.2Gy /fraction) or 63Gy (2.1Gy / fraction) respectively for exclusive RTCT treatment and adjuvant RTCT or RT treatment PTV intermediate risk: 60 Gy (2.0Gy /fraction) PTV low risk: 54Gy (1.8Gy /fraction) Results: From January 2011 to July 2015, 48 patients (mean age 60.9 years; range 33-87) with histologically confirmed diagnosis of oral cancer were treated. At analysis 30 patients (62.5%) underwent surgically treatment and 18 (37.5 %) performed exclusive RTCT treatment. Twentyfour patients were treated with radiochemotherapy or radiotherapy plus molecular-target therapy; in 20 patients (83%) was administered CDDP; in 4 patients (17%) in combination with RT was administered Erbitux. Relapses were divided into local (on T), regional (on N) and locoregional (if the recurrences were on T and N) and classified, after the merger of radiological imaging with radiation therapy planning; in "in field" (within the PTV high risk) and "out field" (without PTV high risk) After a median follow-up of 19.8 months (range 3-62 months), six patients (12.5%) developed local recurrence "in field" and two patients (4.2%) reported locoregional relapse on field. There were not "out field" recurrences. Of six patients relapsed 2 (33.3%) underwent salvage surgery and subsequent CT; 3 (33.3%) underwent second line CT according to Extreme schedule and 1 patient (2%) didn't any systemic treatment but only support care due to comorbidities and scarce performance status. At the date of abstract submission 3/6 patients died while the others are still alive; overall 5/48 patients (10.4 %) died and only 2 died for cancer-related causes and three for comorbidities.
Computed tomography (CT) has become an indispensable tool in oncological imaging. Ionising radiation is cumulative and carries a stochastic risk of malignancy. The implementation of dose reference levels (DRLs) for imaging procedures using ionising radiation is mandated by European Commission directive 97/43 EURATOM. There are currently no dose guidelines for radiation therapy CT of the head and neck (H&N) region. The propose of this research is to establish if variation exists in dose delivered by Irish centres; establish a national DRL for H&N CT scanning in radiation therapy and compare the national DRL with a European sample.
Material and Methods:
All radiation therapy centres in Ireland and a selection of European centres were invited to complete a dose audit survey for 10 average-sized H&N patients undergoing a CT localisation scan. Data on CTDIvol, DLP, mAs, tube voltage, number of scan phases and scan length was collected.
Results: Surveys were returned by five Irish centres, representing a 42% response rate and one European centre. Significant variation was found in the mean DLP, CTDIvol and scan lengths. Based on the rounded 75th percentile of the mean DLP and CTDIvol, the proposed Irish DRL is 1025.41mGy cm and 20.97mGy, respectively. Based on the European survey the DRLs for DLP and CTDIvol were 680.12mGy cm and 21.85mGy, respectively. Material and Methods: Materials and methods : In this study were enrolled 48 patients with oral cancer diagnoses underwent postoperative RT or exclusive RT-CT treatment. The RT was performed with intensity-modulated radiotherapy (IMRT) technique and LINAC DHX of Varian System. All patients were treated at the department of Radiotherapy, University of Pisa. In patients non treated surgically or operated with major risk factors (positive margins, Extracapsular extension) RT treatment was performed in combination with chemotherapy (CT) or molecular-target therapy. Again patients operated with presence of minor risk factors (positive lymph nodes, lymphatic vascular invasion, perineural invasion) underwent only RT treatment. The volumes were defined as follows: PTV high risk: 66Gy (2.2Gy /fraction) or 63Gy (2.1Gy / fraction) respectively for exclusive RTCT treatment and adjuvant RTCT or RT treatment PTV intermediate risk: 60 Gy (2.0Gy /fraction) PTV low risk: 54Gy (1.8Gy /fraction) Results: From January 2011 to July 2015, 48 patients (mean age 60.9 years; range 33-87) with histologically confirmed diagnosis of oral cancer were treated. At analysis 30 patients (62.5%) underwent surgically treatment and 18 (37.5 %) performed exclusive RTCT treatment. Twentyfour patients were treated with radiochemotherapy or radiotherapy plus molecular-target therapy; in 20 patients (83%) was administered CDDP; in 4 patients (17%) in combination with RT was administered Erbitux. Relapses were divided into local (on T), regional (on N) and locoregional (if the recurrences were on T and N) and classified, after the merger of radiological imaging with radiation therapy planning; in "in field" (within the PTV high risk) and "out field" (without PTV high risk) After a median follow-up of 19.8 months (range 3-62 months), six patients (12.5%) developed local recurrence "in field" and two patients (4.2%) reported locoregional relapse on field. There were not "out field" recurrences. Of six patients relapsed 2 (33.3%) underwent salvage surgery and subsequent CT; 3 (33.3%) underwent second line CT according to Extreme schedule and 1 patient (2%) didn't any systemic treatment but only support care due to comorbidities and scarce performance status. At the date of abstract submission 3/6 patients died while the others are still alive; overall 5/48 patients (10.4 %) died and only 2 died for cancer-related causes and three for comorbidities.
Conclusion

Conclusion:
The results of our study confirm the data reported in literature regarding the locoregional recurrences of oral cancer treated with radiotherapy. In field locoregional relapse seems to be the main cause of IMRT treatment failure regardless the patient underwent at surgery treatment or not. Purpose or Objective: Bladder preparatory protocols are used in prostate cancer (PCa) radiotherapy (RT) prior to simulation (Sim) imaging, and thereafter prior to each fraction of RT. Patients are asked to drink, and hold without voiding, a constant volume of water. Distension of the bladder reduces the volume of the bladder irradiated to high doses. A study of online image-guided radiotherapy (IGRT) in bladder cancer showed that inter-and intra-fraction reproducibility was mostly insensitive to degree of bladder filling. Radiographer students were asked to test the analogous hypothesis for inter-fraction reproducibility in bladder volume over 7 weeks of PCa IGRT.
Material and Methods:
An audit of PCa IGRT found 96 cases within 1 year of study commencement. 56/96 were locally advanced PCa homogeneously treated with bladder preparation instructions, daily online cone-beam CT (CBCT) verification and 28Gy sequential boost to gland only following 50Gy to gland plus seminal vesicles by normo-fractionated IMRT. 42 were complete cases in which bladders had been consistently outlined at Sim and 7 CBCTs weekly. 30/42 men agreed to hold 300mL of water each session, but in practice only 26/42 were able to comply throughout treatment. 12/42 men declined the drinking instructions outright.
